CHF-6333
- Generic Name
- CHF-6333
- Drug Type
- Small Molecule
- Chemical Formula
- C28H31F3N6O6S
- CAS Number
- 1613621-54-7
- Unique Ingredient Identifier
- Q0656F336Y
Non-Cystic Fibrosis Bronchiectasis Market Expected to Reach USD 7.5 Billion by 2035, Driven by Novel Therapies
• The Non-Cystic Fibrosis Bronchiectasis (NCFB) market is projected to grow from USD 1.7 billion in 2024 to USD 7.5 billion by 2035, representing a robust CAGR of 14.62%.
• Advancements in diagnostic technologies, including high-resolution computed tomography, molecular tests, and AI-based imaging, are significantly improving early detection and treatment planning for NCFB patients.
• Several promising therapies are in late-stage development, including Insmed's brensocatib, which recently had its NDA accepted by the FDA after showing significant reduction in pulmonary exacerbations in Phase 3 trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath